ScinnoHub Announces NMPA Approval of its Investigational New Drug (IND) Application for BT-101094

Chengdu, China, July 29, 2021-ScinnoHub pharmaceuticals announces IND approval from China National Medical Products Administration (NMPA) for Phase 1 clinical trial of BT-101094. BT-101094 is a novel NTRK/ROS1/ALK/RET inhibitor for the treatment of advanced solid tumors.

About ScinnoHub Pharmaceuticals

ScinnoHub Pharmaceuticals focuses on the development of innovative small-molecule drugs and precision therapeutic platforms with a broad pipeline covering therapeutic areas, including cancer and autoimmune diseases, as well as targeted radioligand therapy and RNA splicing technologies.

At present, ScinnoHub has two first-in-class drugs at clinical stages of which BT-1053 is undergoing Phase 1 clinical trial and BT-101094 receives IND approval.